title: [Relationship between clinical findings of patients with bullous pemphigoid and antigens recognized by their circulating antibasement membrane zone antibodies].
abstract: BACKGROUND
  Clinical features and extent of bullous pemphigoid lesions differed widely among patients. The pathogenic role of anti-BPAG2 antibodies has been recently demonstrated. The aim of this study was to analyze the relationship between clinical features of bullous pemphigoid patients and the antigens recognized by their serum.
  
  
  METHODS
  One hundred and twelve bullous pemphigoid patients were included in this prospective multicenter study. Inclusion criteria were the following: 1) diagnosis of bullous pemphigoid established on the presence of 3 of the 4 clinical features of bullous pemphigoid, histological picture of bullous pemphigoid and positive direct immunofluorescence; 2) serum available for immunoblotting studies. The clinical and biological findings were prospectively recorded on standard forms. Sera were collected and analyzed using indirect immunofluorescence and immunoblotting on human epidermal extracts.
  
  
  RESULTS
  Analysis of patient's clinical features depending on the antigens recognized by their serum showed that patients whose serum contained anti-BPAG1 antibodies had more frequently pruritus, blisters on the lower limbs and a positive indirect immunofluorescence. Patients whose serum contained anti-BPAG2 antibodies had blisters more frequently localized on the head, and a more frequently negative indirect immunofluorescence. Patients whose serum was negative by immunoblotting had less frequently urticarial and/or eczematous lesions, bullae less frequently localized on the lower part of the trunk, abdomen and lower limbs, lower eosinophilia and a more frequently negative indirect immunofluorescence.
  
  
  CONCLUSIONS
  Patients with circulating anti-BPAG1 antibodies exhibited the most typical, clinical and biological features of bullous pemphigoid.
authors.affiliation: Clinique Dermatologique, INSERM U 519, CHU de Rouen.
authors.forename: A
authors.initials: A
authors.lastname: Gary
authors.forename: P
authors.initials: P
authors.lastname: Carvalho
authors.forename: J-B
authors.initials: JB
authors.lastname: Louison
authors.forename: M-F
authors.initials: MF
authors.lastname: Helot
authors.forename: D
authors.initials: D
authors.lastname: Gilbert
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: J-C
authors.initials: JC
authors.lastname: Roujeau
authors.forename: C
authors.initials: C
authors.lastname: Bedane
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
authors.forename: L
authors.initials: L
authors.lastname: Vaillant
authors.forename: B
authors.initials: B
authors.lastname: Dreno
authors.forename: P
authors.initials: P
authors.lastname: Saiag
authors.forename: E
authors.initials: E
authors.lastname: Tancrede-Bohin
authors.forename: P
authors.initials: P
authors.lastname: Plantin
authors.forename: M
authors.initials: M
authors.lastname: D'Incan
authors.forename: B
authors.initials: B
authors.lastname: Sassolas
authors.forename: C
authors.initials: C
authors.lastname: Lok
authors.forename: B
authors.initials: B
authors.lastname: Labeille
authors.forename: C
authors.initials: C
authors.lastname: Pauwels
authors.forename: O
authors.initials: O
authors.lastname: Chosidow
authors.forename: C
authors.initials: C
authors.lastname: Picard
authors.forename: F
authors.initials: F
authors.lastname: Loche
authors.forename: J-C
authors.initials: JC
authors.lastname: Guillaume
authors.forename: P
authors.initials: P
authors.lastname: Joly
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000097:blood*; D001485:Basement Membrane / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D010391:Pemphigoid, Bullous / Q000097:blood* / Q000276:immunology*; D011446:Prospective Studies
chemical_list: D001323:Autoantibodies; D001324:Autoantigens